Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Sistemic And Roslin Working Together on Stem Cells

By R&D Editors | May 10, 2011

Sistemic Ltd and Roslin Cells Ltd signed a Memorandum of Understanding to promote the development of new technologies for the standardisation of the manufacture of stem cells for their use in cell therapy and drug development screening. Both parties believe that only through the development of stem cell standardisation can the full potential of this major opportunity be unlocked.

Sistemic believes that this research has the potential to greatly advance the use of stem cells for cell therapies and research. Jim Reid, Sistemic’s CEO commented “Standardisation is a key step in the broader exploitation of any technology. We have been using our SistemQC microRNA based service with clients working in these fields to help them gain a greater molecular understanding of their stem cell systems and have built a comprehensive understanding of the issues this sector currently faces. We have been looking both at early characterisation during the R&D phase, right through to generating microRNA fingerprints which can be used in the release of products from manufacture. We have been finding that there is a general consensus within the stem cell community that the currently available tools and technologies are not truly fit for purpose. Broader utility will be driven by better standardisation. As more and more of these developments enter clinical testing and subsequent market launch the role for new tools and technologies to really understand these systems is essential. We believe that our SistemQC, microRNA approach will play a key part in delivering these enhanced tools and in collaboration with Roslin set the standard for stem cell characterisation and quality.”

Roslin Cells current stem cells benefit from being highly characterised and thoroughly tested in its cGMP compliant facility and they are recognised as one of the world’s leading centers in this field. Roslin, aim to be at the forefront of stem cell characterisation and as such the collaboration with Sistemic is a natural fit to develop the highest standards for stem cell production, from development, through scale up and the release of high quality cells following manufacture. Aidan Courtney, CEO of Roslin commented that “The characterisation of both primary tissue and of cells in culture is fundamental to our operation. It underpins our ability to produce the highest possible quality of cells for use in cell therapies and as research tools. Data from cell characterisation tests are an essential element of what we provide to our customers and collaborators. This collaboration with Sistemic will enable us to improve our production processes and deliver more extensive and valuable data to those using our cells.”

Date: May 10, 2011
Source: Sistemic Ltd and Roslin Cells Ltd 

Related Articles Read More >

2025 R&D layoffs tracker: 83,543 and counting
Health-related innovation in Morocco highlighted by resident inventor patenting activity
ARPA-H funds $29M Ginkgo-led project to reshore pharma supply chains using wheat germ tech
DNA microscope offers new 3D view of organisms from the inside out
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE